Lysophosphatidic Acid Increases the Electrophysiological Instability of Adult Rabbit Ventricular Myocardium by Augmenting L-Type Calcium Current

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Wei, Yong ^a,b   Zhao, Li qun ^a   Qi, Bao zhen ^a   Xiao, Xing ^c   He, Li ^c   Zhou, Gen qing ^a   Chen, Song wen ^a   Li, Hong li ^a   Ruan, Lei ^c   Zhang, Cun tai ^c   Liu, Shao wen ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b Shanghai Songjiang Centeral Hospital   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; DELAYED RECTIFIER POTASSIUM CHANNEL; LYSOPHOSPHATIDIC ACID;

ACTION POTENTIAL DURATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CALCIUM CURRENT; CONTROLLED STUDY; DENSITY; ENDOCARDIUM; EXPERIMENTAL RABBIT; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE; HEART MUSCLE CELL; HEART REPOLARIZATION; MALE; MEMBRANE POTENTIAL; MEMBRANE STEADY POTENTIAL; NONHUMAN; OVERSHOOT; POTASSIUM CURRENT; QT INTERVAL;

ACTION POTENTIALS; ANIMALS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; HEART VENTRICLES; LYSOPHOSPHOLIPIDS; MALE; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PERTUSSIS TOXIN; RABBITS; VENTRICULAR FUNCTION;

ORYCTOLAGUS CUNICULUS;

EID: 84866666332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045862     Document Type: Article

References (40)

1. Pagès C, Simon MF, Valet P, Saulnier-Blache JS, (2001) Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 64: 1-10.
2. Rancoule C, Pradère JP, Gonzalez J, Klein J, Valet P, et al. (2011) Lysophosphatidic acid-1-receptor targeting agents for fibrosis. Expert Opin Investig Drugs 20: 657-667.
3. Tomar A, George SP, Mathew S, Khurana S, (2009) Differential effects of lysophosphatidic acid and phosphatidylinositol 4,5-bisphosphate on actin dynamics by direct association with the actin-binding protein villin. J Biol Chem 284: 35278-35282.
4. Cremers B, Flesch M, Kostenis E, Maack C, Niedernberg A, et al. (2003) Modulation of myocardial contractility by lysophosphatidic acid (LPA). J Mol Cell Cardiol 35: 71-80.
5. Meyer zu Heringdorf D, Jakobs KH, (2007) Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 1768: 923-940.
6. Noguchi K, Ishii S, Shimizu T, (2003) Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278: 25600-25606.
7. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J, (2006) GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 281: 23589-23597.
8. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N, (2007) The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 363: 861-866.
9. Lin ME, Herr DR, Chun J, (2010) Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 91: 130-138.
10. Tigyi G, Parrill AL, (2003) Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 42: 498-526.
11. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, et al. (2003) Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR gamma agonist. Proc Natl Acad Sci USA 100: 131-136.
12. Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, et al. (2006) Different residues mediate recognition of 1-O-Oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor γ. J Biol Chem 281: 3398-3407.
13. Fukushima N, Chun J, (2001) The LPA receptors. Prostaglandins Other Lipid Mediat 64: 21-32.
14. Smyth SS, Cheng HY, Miriyala S, Panchatcharam M, Morris AJ, (2008) Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim Biophys Acta 1781: 563-570.
15. Yang L, Andrews DA, Low PS, (2000) Lysophosphatidic acid opens a Ca(++) channel in human erythrocytes. Blood 95: 2420-2425.
16. Wang J, Carbone LD, Watsky MA, (2002) Receptor-mediated activation of a Cl- current by LPA and S1P in cultured corneal keratocytes. Invest Ophthalmol Vis Sci 43: 3202-3208.
17. Cohen A, Sagron R, Somech E, Segal-Hayoun Y, Zilberberg N, (2009) Pain-associated signals, acidosis and lysophosphatidic acid, modulate the neuronal K2P2.1 channel. Mol Cell Neurosci 40: 382-389.
18. Akita T, Joyner RW, Lu C, Kumar R, Hartzell HC, (1994) Developmental changes in modulation of calcium currents of rabbit ventricular cells by phosphodiesterase inhibitors. Circulation 90: 469-478.
19. Yan GX, Wu Y, Liu T, Wang J, Marinchak RA, et al. (2001) Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103: 2851-2856.
20. Zaniboni M, Pollard AE, Yang L, Spitzer KW, (2000) Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling. Am J Physiol Heart Circ Physiol 278: H677-H687.
21. Hondeghem LM, Carlsson L, Duker G, (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004-2013.
22. Kaufman ES, (2011) Arrhythmic risk in congenital long QT syndrome. J Electrocardiol 44: 645-649.
23. Shimizu W, Horie M, Ohno S, Takenaka K, Yamaguchi M, et al. (2004) Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 44: 117-125.
24. Parrill AL, Sardar VM, Yuan H, (2004) Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands. Semin Cell Dev Biol 15: 467-476.
25. Spector AA, (2003) Plaque rupture, lysophosphatidic acid, and thrombosis. Circulation 108: 641-643.
26. Karliner JS, (2002) Lysophospholipids and the cardiovascular system. Biochim Biophys Acta 1582: 216-221.
27. Tokumura A, Yotsumoto T, Masuda Y, Tanaka S, (1995) Vasopressor effect of lysophosphatidic acid on spontaneously hypertensive rats and Wistar Kyoto rats. Res Commun Mol Pathol Pharmacol 90: 96-102.
28. Xu YJ, Rathi SS, Zhang M, Bhugra P, Dhalla NS, (2002) Mechanism of the positive inotropic effect of lysophosphatidic acid in rat heart. J Cardiovasc Pharmacol Ther 7: 109-115.
29. Hilal-Dandan R, Means CK, Gustafsson AB, Morissette MR, Adams JW, et al. (2004) Lysophosphatidic acid induces hypertrophy of neonatal cardiac myocytes via activation of Gi and Rho. J Mol Cell Cardiol 36: 481-493.
30. Wei L, (2004) Lysophospholipid signaling in cardiac myocyte hypertrophy. J Mol Cell Cardiol 36: 465-468.
31. Chen J, Chen Y, Zhu W, Han Y, Han B, et al. (2008) Specific LPA receptor subtype mediation of LPA-induced hypertrophy of cardiac myocytes and involvement of Akt and NFkappaB signal pathways. J Cell Biochem 103: 1718-1731.
32. Chang YJ, Kim YL, Lee YK, Sacket SJ, Kim K, et al. (2007) Dioleoyl phosphatidic acid increases intracellular Ca2+ through endogenous LPA receptors in C6 glioma and L2071 fibroblasts. Prostaglandins Other Lipid Mediat 83: 268-276.
33. Xu YJ, Saini HK, Cheema SK, Dhalla NS, (2005) Mechanisms of lysophosphatidic acid-induced increase in intracellular calcium in vascular smooth muscle cells. Cell Calcium 38: 569-579.
34. Ohata H, Yamada H, Momose K, (2011) Lysophosphatidic acid induces shear stress-dependent Ca2+ influx in mouse aortic endothelial cells in situ. Exp Physiol 96: 468-475.
35. Chemin J, Patel A, Duprat F, Zanzouri M, Lazdunski M, et al. (2005) Lysophosphatidic Acid-operated K+ Channel. J Biol Chem 280: 4415-4421.
36. de Jong JS, Verkerk AO, van Borren MM, Zakhrabova-Zwiauer OM, Nieuwland R, et al. (2011) Activated human platelet products induce proarrhythmic effects in ventricular myocytes. J Mol Cell Cardiol 51: 347-356.
37. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, et al. (2004) Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 103: 2096-2104.
38. Moolenaar WH, van Meeteren LA, Giepmans BN, (2004) The ins and outs of lysophosphatidic acid signaling. Bioessays 26: 870-881.
39. Swarthout JT, Walling HW, (2000) Lysophosphatidic acid: receptors, signaling and survival. Cell Mol Life Sci 57: 1978-1985.
40. Chen X, Yang XY, Wang ND, Ding C, Yang YJ, et al. (2003) Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction. Scand J Clin Lab Invest 63: 497-503.